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Abstract
Intact mitochondria were incubated with and without calcium in solutions of chenodeoxycholate, ursodeoxycholate, or
their conjugates. Glutamate dehydrogenase, protein and phospholipid release were measured. Alterations in membrane and
organelle structure were investigated by electron paramagnetic resonance spectroscopy. Chenodeoxycholate enhanced
enzyme liberation, solubilized protein and phospholipid, and increased protein spin label mobility and the polarity of the
hydrophobic membrane interior, whereas ursodeoxycholate and its conjugates did not damage mitochondria. Preincubation
with ursodeoxycholate or its conjugate tauroursodeoxycholate for 20 min partially prevented damage by chenodeoxycholate.
Extended preincubation even with 1 mM ursodeoxycholate could no longer prevent structural damage. Calcium (from
0.01 mM upward) augmented the damaging effect of chenodeoxycholate (0.15^0.5 mM). The combined action of 0.01 mM
calcium and 0.15 mM chenodeoxycholate was reversed by ursodeoxycholate only, not by its conjugates tauroursodeox-
ycholate and glycoursodeoxycholate. In conclusion, ursodeoxycholate partially prevents chenodeoxycholate-induced
glutamate dehydrogenase release from liver cell mitochondria by membrane stabilization. This holds for shorter times
and at concentrations below 0.5 mM only, indicating that the different constitution of protein-rich mitochondrial membranes
does not allow optimal stabilization such as has been seen in phospholipid- and cholesterol-rich hepatocyte cell membranes,
investigated previously. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Accumulation of endogenous hydrophobic bile
acids in serum and hepatocytes probably contributes
to cell damage in chronic cholestatic liver diseases,
leading to an increased release of liver enzymes [1,2].
Hydrophobic bile salts, such as chenodeoxycholate
(CDC), have been shown to damage isolated cell
membranes [3], impair mitochondrial respiration
[4,5], liberate intracellular enzymes from cultured
hepatocytes [6], and induce cholestasis and hepato-
cellular damage in animal models [7].
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In patients with primary biliary liver diseases,
treatment with ursodeoxycholate (UDC) alleviates
symptoms [8], reduces liver enzyme levels in serum
[1,9,10], and slows the histological progression in the
early stages of the disease [11]. The drop in serum
levels of the speci¢c mitochondrial enzyme glutamate
dehydrogenase (GLDH) is especially rapid and can
decrease by as much as 80% in the third week of
UDC therapy [12]. Serum GLDH provides a more
clearcut indication of liver damage than other hep-
atic enzymes, such as alanine aminotransferase or
aspartate aminotransferase, because liberation of
GLDH only occurs upon cell necrosis [13^15]. The
bene¢cial e¡ect of UDC therapy seems to be partly
due to the gradual replacement of hydrophobic bile
acids in serum and bile [16,17]. However, in vitro
investigations have shown that UDC and UDC con-
jugates ameliorate damage caused by hydrophobic
bile salts not only in isolated hepatocytes [6,18],
but also in red blood cells [18], and in erythrocyte
and liver cell membranes [3,19]. Since red blood
cells and isolated membranes do not possess organ-
elles to metabolize bile acids, these results indicate a
direct interaction of UDC with plasma membranes
[20].
Since UDC can reduce cell plasma membrane
damage by hydrophobic bile acids, it would be inter-
esting to ¢nd out whether UDC might also protect
mitochondrial membranes from accumulated toxic
bile acids and thus reduce the GLDH release in pa-
tients with primary biliary cirrhosis. We therefore
investigated the in£uence of CDC, UDC, and their
conjugates on the liberation of GLDH, protein and
phospholipid from isolated rat liver mitochondria
and their e¡ect on membrane protein mobility, mem-
brane polarity, and mitochondrial structure. Since
incubation of isolated rat hepatocytes with hydro-
phobic bile acids has been shown to increase levels
of intracellular calcium [21^24], which is believed to
accelerate cell death [25^27], we also examined the
combined e¡ect of bile salts and various calcium
concentrations. Since bile acid concentrations in the
liver tissue of healthy persons are unknown and dur-
ing cholestasis reach 0.2^0.8 mM [28,29], and since
all publications cited in the text were performed with
concentrations between 0.1 and 1 mM, in our experi-
ments we used concentrations between 0.15 and
1.0 mM.
2. Materials and methods
2.1. Materials
Bile salts were obtained from Calbiochem (San
Diego, CA, USA), purity was 99% as determined
by thin-layer chromatography. 4-Maleimido-2,2,6,
6,-tetramethylpiperidinooxyl (4-maleimido-TEMPO)
spin label and the 16-doxyl-stearic acid (16-DSA)
spin label were purchased from Aldrich (Steinheim,
Germany). N-Tris[hydroxymethyl]methyl-2-amino-
ethanesulfonic acid (TES) was purchased from Sigma
(Deisenhofen, Germany), and all other chemicals
were obtained from Merck (Darmstadt, Germany)
in analytical grade.
2.2. Isolation of mitochondria
Mitochondria were isolated from rat livers accord-
ing to a slightly modi¢ed method of Bustamente et
al. [30]. All animals were handled in compliance with
the German animal protection laws. Wistar rats
weighing 200^280 g were anesthetized with diethyl
ether, the abdominal cavity was opened and the liver
removed after a short perfusion with 0.9% NaCl to
remove blood. The liver was then rinsed in ice-cold
bu¡er (300 mM mannitol, 10 mM TES, 1 mM ethyl-
enediaminetetraacetic acid (EDTA), pH 7.4) and cut
with scissors into approx. 2 mm3 pieces. The minced
liver was transferred to a 100 ml glass potter in 50 ml
bu¡er and homogenized on ice using a motor-driven
te£on pestle (Janke and Kunkel KG, IKA Werk,
Staufen, Germany).
The homogenate was then centrifuged in a SS-34
rotor at 600Ug for 10 min at 4‡C using a Sorvall
RC-5B refrigerated superspeed centrifuge (DuPont
Instruments, Bad Nauheim, Germany). The SS-34
rotor and Sorvall centrifuge were used in all the fol-
lowing centrifugation steps which were carried out at
4‡C. The supernatant was centrifuged at 8000Ug for
10 min and the supernatant from this step was dis-
carded. The pellets were gently resuspended in bu¡er
and centrifuged at 600Ug for 10 min. The pellets
were discarded and the supernatant centrifuged at
8000Ug for 10 min. These pellets were gently resus-
pended and combined before being ¢nally centri-
fuged at 8000Ug for 10 min to yield the puri¢ed
mitochondrial fraction and a clear supernatant. The
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mitochondrial pellet was then gently resuspended in
bu¡er (1 ml, about 25 mg protein) and used in the
experiments.
Integrity of mitochondrial preparations was
checked by means of respiration measurements [31].
2.3. Determination of glutamate dehydrogenase
activity
Glutamate dehydrogenase was determined by an
‘Optimized Standard Method’ of the German Society
for Clinical Chemistry using GLDH test substances
from Boehringer, Mannheim, Germany. In principle,
NADH decrease vs. time is measured photometri-
cally at 340 nm and at 25‡C.
GLDH activity is known to be inhibited by a wide
range of substances [32,33]. Therefore, experiments
were carried out to check that the incubation media
used for the mitochondria did not directly inhibit
GLDH. The commonly used bu¡er substances (N-
[2-hydroxyethyl-piperazine-NP-2-ethane-sulfonic acid
(HEPES), triethanolamine [2,2P,2Q-nitrilotriethanol]
hydrochloride (TEA), and tris(hydroxymethyl)-ami-
nomethane (Tris) revealed inhibitory e¡ects on the
GLDH activity in vitro, whereas in N-tris[hydroxy-
methyl]methyl-2-aminoethanesulfonic acid (TES) en-
zyme activity remained stable. Interactions between
bile salts, calcium and GLDH were investigated us-
ing GLDH extracted from rat liver and human liver
biopsy material. Although high concentrations of
bile salts were found to inhibit enzyme activity, up
to 1 mM CDC and 2 mM UDC showed no direct
inhibitory e¡ect on GLDH activity in vitro, nor did
any of the calcium bu¡ers that were tested.
To measure the e¡ect of di¡erent bile salts or cal-
cium concentrations on the release of GLDH from
mitochondria, 20 Wl of mitochondrial suspension
(0.5 mg protein) was incubated either with 980 Wl
of bu¡er (300 mM mannitol, 10 mM TES, 1.0 mM
EDTA, pH 7.4) which served as a control, or with a
solution of 0.2^1.0 mM CDC (or conjugates) in
bu¡er (pH 7.4), or with a solution of 0.2^2.0 mM
UDC (or conjugates) in bu¡er pH 7.4, or with bu¡er
without EDTA containing 0.001^1.0 mM calcium (in
order to achieve the low concentration of 1 WM, the
bu¡er was passed through a Chelex column and cal-
cium was checked with a Ca2 electrode). After in-
cubation, the mitochondrial suspension was centri-
fuged for 2 min at 9000Ug in a Sigma centrifuge
202 M (Sigma, Osterode, Germany), and the
GLDH activity was determined in the supernatant.
In experiments where mitochondria were incu-
bated with two di¡erent bile salt solutions, 20 Wl of
mitochondrial suspension was ¢rst incubated either
with 490 Wl bu¡er (controls), or with 490 Wl 0.2^
2.0 mM UDC (or conjugates) in bu¡er for 20 min.
Subsequently, 490 Wl of 0.3^1.0 mM CDC was added
(¢nal concentration of CDC 0.15^0.5 mM), and the
mitochondria were incubated in the mixed solution
for a further 10 min. The mitochondrial suspension
was then centrifuged and the GLDH activity deter-
mined in the supernatant as described before.
2.4. Electron paramagnetic resonance spectroscopy
(EPR)
EPR enables the measurement of changes in mem-
brane structure by incorporating paramagnetic re-
porter groups into the membrane (spin labels), which
give characteristic spectra upon excitation with mi-
crowaves in a magnetic ¢eld.
To study the e¡ect of bile salts on the integrity of
the mitochondrial membranes we used the 4-malei-
mido-TEMPO label as well as the 16-DSA spin label.
The 4-maleimido-TEMPO label binds to the sulf-
hydryl groups of proteins [34^36] and is therefore
suitable for measuring changes in the structure of
protein-rich membranes, such as the inner membrane
of mitochondria [37,38]. The ratio of the height of
the midline to the height of the high¢eld line of the
EPR spectrum (h0/h31) re£ects the freedom of mo-
tion of this label at its binding site, and thus provides
a parameter for the mobility of thiol groups within
the membrane. A high ratio re£ects a low freedom of
motion, a low ratio a large freedom of motion of the
label. If the ordered structure of the membrane pro-
teins is disrupted due to the solubilization of mem-
brane components, this is re£ected in an increased
mobility of the spin label in accordance with a de-
creased ratio h0/h31. 16-DSA in the membrane inte-
rior reveals a partitioned third line, indicating that
the label experiences environments of di¡erent polar-
ity. A very reliable parameter of the environment of
this spin label, closely corresponding to intensity
changes in the third line, is the coupling constant
aN [3]. Using these two types of spin label, we obtain
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information about mobility of protein reactive
groups as well as about polarity changes in the hy-
drophobic membrane compartment (either in the lip-
id phase or in the lipid/protein interface). The exper-
imental procedure for determining the e¡ect of bile
salts on EPR spectra was as follows: 40 Wl of mito-
chondrial suspension containing 1 mg protein was
diluted to 50 Wl with bu¡er and then incubated for
1 min with 10 nmol (2 Wl) of spin label. 950 Wl bu¡er
was then added, or 0.2^1.0 mM CDC (or conjugates)
(20 min) in bu¡er, or 475 Wl 1.0 mM UDC (or con-
jugates) followed by addition of 475 Wl 0.3^1.0 mM
CDC (10 min). All incubations were carried out at
25‡C and pH 7.4. The suspension was then centri-
fuged for 2 min in an Eppendorf centrifuge at
9000Ug and the supernatant discarded. The mito-
chondrial pellet was then resuspended in 50 Wl bu¡er,
drawn up into a 50 Wl capillary, placed in the cavity
of the EPR spectrometer (Magnet B-E-25; Bruker,
Karlsruhe, Germany) and measured.
2.5. Protein and phospholipid determination
Protein was measured according to Lowry [39] us-
ing bovine serum albumin as a standard. Protein
content of the mitochondrial suspension was about
25 mg/ml. Phospholipid measurement was carried
out with a Boehringer Mannheim enzymatic test kit
(Boehringer, Mannheim, Germany; the kit does not
recognize cardiolipin).
2.6. Statistical analysis
All results are the mean þ S.D. of at least six indi-
vidual measurements. Statistical signi¢cance was as-
sessed using the unpaired Student’s t-test.
3. Results
Fig. 1 shows GLDH activities found in the super-
natants of mitochondria incubated for di¡erent times
in the presence of 1 mM CDC or TCDC. Control
values for GLDH reach 0.084 þ 0.026 U/mg protein.
Maximal values of 2.36 þ 0.51 U/mg protein were
obtained after complete dissolution of the mem-
branes by Triton X-100 (considered as 100% leakage
in the ¢gures). The latter range of values (2 U/mg
protein) is clearly reached by incubation with 1 mM
TCDC for 60 min. For comparison, after CDC in-
cubation, only about 1 U/mg protein is found.
GLDH release of the controls does not appreciably
change during the incubation times between 5 and
60 min.
Fig. 2 presents the action of CDC and calcium in
rising concentrations at 20 min incubation time.
Fig. 1. GLDH activities in the supernatants of mitochondria incubated with 1 mM CDC (F), or 1 mM TCDC (b), controls (R) for
di¡erent times (**P6 0.01).
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Clearly, GLDH release in the presence of 0.01 mM
Ca2 is increased about 4-fold at 1 mM CDC, when
compared to Fig. 1. Interestingly, at 0.1^1.0 mM
Ca2, GLDH release is decreased under all condi-
tions compared to the results obtained at 0.01 mM
Ca2. We were therefore interested to see results on
membrane structure, in particular under the in£uence
of di¡erent concentrations of calcium. Using the
4-maleimido-TEMPO spin label, mobility parameter
h0/h31 does not change up to 0.01 mM Ca2, but it is
de¢nitely increased at 0.1^1.0 mM Ca2 (Fig. 3). The
lipid-oriented spin label 16-DSA revealed a signi¢-
cant increase of aN at a concentration of 0.1 mM
Ca2 (Table 1).
In the presence of 0.5 mM CDC and at increasing
Ca2, there is a signi¢cant increase of all aN values at
0.01 mM Ca2 and above (Table 1). From these
results the exaggerating in£uence of Ca2 at
0.01 mM on CDC-induced membrane leakiness to-
wards GLDH is also underlined by EPR spectro-
scopy. GLDH activities in the supernatant, however,
were also found to be increased, though to a lower
Fig. 2. GLDH activities in the supernatants of mitochondria incubated in the presence of 0.3 mM CDC (F), 0.5 mM CDC (8),
1 mM CDC (b), controls (R), and at di¡erent concentrations of Ca2 (*P6 0.05, **P6 0.01).
Fig. 3. In£uence of Ca2 on the structure of mitochondria: EPR spin label experiments with 4-maleimido-TEMPO; mobility charac-
teristics were measured using h0/h31 (**P6 0.01).
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extent, at CDC concentrations between 0.5 and 0.8
mM. h0/h31 of the maleimide spin label was concom-
itantly decreased (Fig. 4), indicating progressive mo-
bilization of the labeled protein -SH groups.
At concentrations above 0.8 mM CDC, deteriora-
tion of the mitochondrial membrane structure can be
anticipated. Whereas protein and phospholipid con-
tents of the mitochondrial pellet after incubation
with bu¡ers remains constant, within 60 min in the
presence of 1 mM CDC protein decreased from
around 0.4 mg to 0.15 mg and phospholipids from
around 0.25 to 0.015 mg.
In our further experiments we wanted to ¢nd out
whether UDC preincubation (1.0 mM) might be able
to counteract the deleterious in£uence of 0.5 mM
concentration of CDC. The results are presented in
Table 2. Up to a preincubation time of 20 min with
UDC, we observed a decrease of GLDH liberation
into the bu¡er compared to incubation with CDC in
the absence of UDC. At 30 min preincubation, the
amount of GLDH found is similar in controls (CDC
alone) and UDC-preincubated samples, whereas
after 60 min the amount with UDC tends to increase
further, compared to CDC alone. This adds to the
Table 1
Polarity values (aN) of mitochondria treated with 16-DSA spin label under conditions of increasing calcium concentrations and bile
acids
Control Ca2 0.001 mM Ca2 0.01 mM Ca2 0.1 mM Ca2 1.0 mM
14.48 þ 0.097 14.53 þ 0.127 14.51 þ 0.066 14.934 þ 0.124a 14.49 þ 0.084
CDC 0.5 mM CDC/Ca2 0.001 mM CDC/Ca2 0.01
mM
CDC/Ca2 0.1
mM
CDC/Ca2 1.0
mM
14.77 þ 0.153b 14.65 þ 0.09 15.03 þ 0.29c 15.01 þ 0.103d 14.92 þ 0.08e
CDC 1.0 mM TCDC 1.0 mM TCDC 0.5 mM UDC 0.5 mM TUDC 1.0 mM TUDC 0.5 mM GUDC 1.0 mM
14.83 þ 0.08f 14.81 þ 0.16f 14.46 þ 0.07 14.49 þ 0.08h 14.48 þ 0.29 14.47 þ 0.08 14.44 þ 0.10
aP6 0.01 vs. control; bP6 0.01 vs. control; cP6 0.05 vs. CDC 0.5 mM; dP6 0.01 vs. CDC 0.5 mM; eP6 0.01 vs. CDC 0.5 mM;
f P6 0.01 vs. control; gP6 0.01 vs. control; hP6 0.01 vs. CDC 1.0 mM.
Fig. 4. Mitochondrial GLDH release and changes in the mobility of the 4-maleimido-TEMPO label (h0/h31) of mitochondria incu-
bated for 30 min with increasing CDC concentrations. (F) GLDH activity; (R) h0/h31 (mobility of the spin label; see Section 2).
*P6 0.05, **P6 0.01 vs. controls in bu¡er.
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observation that the amount of protein and phos-
pholipid solubilized after 30 and 60 min preincuba-
tion with UDC was not signi¢cantly di¡erent from
mitochondria incubated with CDC.
In the following experiments we therefore used
preincubation times of 20 min for UDC and the
conjugates and tested a concentration range of 0.2^
2.0 mM, in order to ¢nd out concentration-depend-
ent di¡erences in the inhibition of GLDH release.
Fig. 5 shows that, resembling the positive results of
shorter incubation times, also the smallest concentra-
tion of UDC (0.2 mM) appears to be the most e⁄-
cient, decreasing GLDH liberation at 0.5 mM CDC
by about 30%. The conjugates are either ine⁄cient or
only positively e⁄cient at 1.0 mM concentration.
2.0 mM, however, is a toxic concentration of
TUDC or GUDC, which both increase GLDH lib-
eration compared to 1.0 mM CDC alone. With
0.25 mM CDC, UDC-preincubated samples exhib-
ited lower or equivalent levels of GLDH liberation
when compared to the controls (in the absence of
CDC). There is also a signi¢cant shift of the spin
label mobilities towards the control values, indicating
structural improvement. TUDC preincubated sam-
ples moved into the same direction (Fig. 6).
Finally, we used preincubation for 20 min with
UDC and the conjugates at a concentration of
0.15 mM CDC and 0.01 mM Ca2 (Fig. 7). Under
Table 2
GLDH release from mitochondria treated with 1.0 mM UDC for 5^60 min prior to addition of 0.5 mM CDC for 10 min
Preincubation time in bu¡er or
UDC (min)
Preincubation in bu¡er GLDH activity
(U/mg protein)
Preincubation in UDC GLDH activity
(U/mg protein)
0 0.084 þ 0.026
5 0.166 þ 0.010 0.130 þ 0.016**
10 0.182 þ 0.018 0.148 þ 0.006**
20 0.209 þ 0.009 0.187 þ 0.014*
30 0.204 þ 0.013 0.212 þ 0.019
60 0.254 þ 0.026 0.283 þ 0.026
*P6 0.05, **P6 0.01, vs. preincubation in bu¡er followed by 1 mM CDC.
Maximum value after Triton X-100: 2.36 þ 0.51 U/mg protein.
Fig. 5. GLDH release from mitochondria incubated for 20 min with 0.2^2.0 mM UDC or bu¡er prior to incubation with 0.5 mM
CDC for 10 min. White bars: preincubation in bu¡er, followed by CDC; vertically hatched bars: preincubation in UDC; horizontally
hatched bars: preincubation in TUDC; black bars: preincubation in GUDC. *P6 0.05, **P6 0.01 vs. controls preincubated in bu¡er
followed by 0.5 mM CDC.
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these conditions the protective in£uence of UDC is
most clearly revealed: we see a GLDH activity di-
minished by about 30% in the supernatant. Under
these conditions, TUDC or GUDC proved to be
insu⁄cient. UDC also prevented structural damage.
This is underlined by the unchanged polarity value in
the presence of UDC (Table 1). This, however, by
itself is not su⁄cient to indicate structural integrity
since similar values can be found for TUDC and
GUDC. For the latter substances, the di¡erent
mode of binding due to probable polar interaction
[3] should therefore be considered.
4. Discussion
The mechanism of the therapeutic e¡ect of UDC
in primary biliary liver diseases is not known. Several
theories have been suggested: replacement of more
apolar bile acids in serum and bile [16,17,40], inhi-
bition of the reabsorption of toxic bile acids in the
intestine [41,42], stimulation of exocytosis and chol-
eresis leading to increased elimination of apolar bile
acids and toxins from the liver [43,44], and a direct
protection of hepatocyte membranes [3,18,20]. The
latter is supported by several investigations showing
a reduction in enzyme release from isolated hepato-
cytes and the preservation of plasma cell membranes
in vitro. The question therefore arises whether the
reduction in GLDH liberation from the liver seen
very early during UDC therapy could possibly be
due to a similar protective e¡ect on mitochondrial
membranes and whether preservation of mitochon-
drial function could be an important aspect of
UDC therapy.
Fig. 6. Release of GLDH and changes in mobility of the 4-mal-
eimido-TEMPO spin label (h0/h31) caused by prior incubation
with bu¡er or with 1 mM UDC or TUDC for 20 min and ad-
dition of 0.25 mM CDC for 10 min. Gray bars: GLDH; b : h0/
h31. *P6 0.05, **P6 0.01 vs. bu¡er/CDC.
Fig. 7. GLDH release from mitochondria treated with 1.0 mM UDC, TUDC or GUDC for 20 min followed by 0.15 mM CDC in
bu¡er with 0.01 mM calcium. GLDH activity in: white bar, bu¡er/calcium+CDC; horizontally hatched bar, 1 mM UDC/cal-
cium+CDC; cross-hatched bar, 1 mM TUDC/calcium+CDC; black bar, 1 mM GUDC/calcium+CDC. **P6 0.01 vs. incubation in
the respective calcium bu¡er with CDC.
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Bile acids have been shown to have a direct inhib-
itory e¡ect on the activity of some liver enzymes [45].
However, since in our experiments inactivation of
human GLDH by UDC only occurred at concentra-
tions above 5.0 mM, it is improbable that the reduc-
tion in GLDH serum levels in patients treated with
UDC is due to a direct inhibition in the liver or
serum. Rat liver GLDH activity also remains unaf-
fected by relatively high concentrations of CDC (1.0
mM) and UDC (2.0 mM).
The destructive e¡ect of CDC and its conjugates
on mitochondria corresponds with the results ob-
tained on basolateral hepatocyte membranes [3], iso-
lated hepatocytes [6] and intact livers [7]. The perfo-
ration and disruption of the mitochondrial
membranes is re£ected in the release of GLDH
from the matrix, the liberation of protein and phos-
pholipid, the increase in 4-maleimido-TEMPO spin
label mobility and of polarity. In accordance with
these observations it has recently been shown that
CDC in a concentration of 0.1 mM, a range which
has also been used in our investigations, inhibits mi-
tochondrial state 3 oxidation and complex I and III
of the electron transport chain [4]. Later, using bile
duct-ligated rats, this group of investigators deduced
the defect to complex I and II (with or without an
additional defect at complex III). Alternatively a sin-
gle defect could exist at complex III [5].
UDC appears not to damage mitochondrial mem-
branes. Prior incubation of mitochondria with UDC
reduces the release of GLDH caused by addition of
0.5 mM CDC. Similar results have been obtained
with UDC and GCDC measuring the mitochondrial
membrane permeability transition (MPT), using bile
acid concentrations of 0.05^0.3 mM [46]. This e¡ect
cannot be attributed to a molecular interaction be-
tween UDC and CDC [3], since incubation in a mix-
ture of the two bile salts without prior incubation in
UDC alone did not prevent GLDH release. The
UDC-induced decrease in mitochondrial permeabil-
ity could be explained by an interaction of this bile
salt with the lipids as well as proteins of the mem-
brane [3,20], causing membrane holes or pores to
seal. This is supported by the observation that
UDC reduces the mobility of the 4-maleimido-TEM-
PO label, indicating normalization of membrane £u-
idity to about the values of controls.
The di¡erence between the e¡ect of UDC on mi-
tochondrial membranes and that already described
for plasma cell membranes [3,20] should probably
be attributed to their di¡erent composition. Cell
membranes are stabilized by cholesterol molecules
inserted between the hydrocarbon chains of the
phospholipid bilayer [48]. On the other hand, the
inner mitochondrial membranes of non-cholestatic
livers contain virtually no (or minimal amounts of)
cholesterol and far less phospholipid, since 75% of
the inner membrane consists of protein. However, in
bile duct-ligated rats the cholesterol content of the
inner mitochondrial membrane was found to be three
times higher, whereas the phospholipid composition
remained unchanged. This probably contributes to or
is a main factor of diminished mitochondrial func-
tion [5].
Because mitochondrial membranes are rather rich
in proteins, the UDC molecule may not remain per-
manently attached and could become liberated from
a membrane destabilized at longer preincubation
times. The temporary nature of the delayed enzyme
release is also shown by the observation that UDC
did not in the long run prevent protein and phospho-
lipid solubilization by CDC or conserve mitochon-
drial structure (not shown).
The protective e¡ects of UDC and TUDC in our
study have been observed with concentrations of
0.2 mM which corresponds to the doses used by
others, who have shown that UDC in concentrations
of 0.03^0.1 mM partially reversed the toxic e¡ects of
lipophilic bile acids on mitochondrial oxidative me-
tabolism [47], and which corresponds to the investi-
gations on MPT mentioned above [46], where doses
of 0.3 mM have been used.
Treatment with bile salts increases cytosolic calci-
um in hepatocytes [21^24] and red blood cells [49],
and excessive calcium is believed to be an important
factor in the process of cell apoptosis/necrosis. In our
experiments increasing the calcium concentration in
the bu¡er to 0.01 mM exacerbated GLDH release
induced by CDC and damaged mitochondrial struc-
ture indicated by mobility changes at membrane pro-
tein sites as well as by alterations in polarity in the
hydrophobic membrane core. By contrast, very high
calcium concentrations (above 0.1 mM) decreased
GLDH release, possibly by preventing the exit of
enzyme due to a surplus of positive charges in the
membrane increasing membrane rigidity. Decreases
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in membrane permeability caused by calcium and
other cations, such as zinc and protons [50], have
been described for plasma membranes [51,52] and
phospholipid bilayers [53], but do not appear to
have been previously reported for mitochondria.
Although intracellular calcium levels in hepato-
cytes are normally about 100^300 nM [21,22,54],
pathophysiological concentrations of bile salts have
been shown to increase the intracellular calcium con-
centration of hepatocytes up to 0.5 WM [24,54,55],
and concentrations of nearly 1.0 WM have also
been measured [54]. Physiological intracellular bile
acid concentrations are uncertain, but are believed
to be in the range of 0.2^0.8 mM [28,29]. Moreover,
the mutual relationship between time of incubation
and concentration of bile acids is completely un-
known. During cholestasis peripheral serum bile
acid concentrations can increase from 0.3^1.3 WM
to more than 250 WM [56]. Therefore it is possible
that in vivo increased cytosolic calcium (liberated
from intracellular stores or absorbed through leaky
membranes) enhances the damaging e¡ect of accu-
mulated toxic bile acids on mitochondria, as shown
in vitro in this study. Particularly at 0.01 mM Ca2
this e¡ect is maximal (Fig. 2), which corresponds
closely to the signi¢cant increase in polarity at this
concentration of Ca2 (Table 1). 0.1 mM Ca2 was
also found in other studies to exhibit maximal e¡ects
on protein secondary structure: there was an en-
hancement of K-helix content and a diminution of
L-structures. Above 0.1 mM Ca2 aggregation and
additional structural change of recoverin was ob-
served [57].
Rigidi¢cation of the membrane in the presence of
Ca2 (0.1 mM) or Ca2 0.01 mM/CDC 0.5 mM is
accompanied by an increased polarity within the
membrane’s hydrophobic interior (Table 1) and en-
hanced release of GLDH (Fig. 2) into the superna-
tant.
1 mM UDC clearly prevents the increase of
GLDH release induced by 0.15 mM CDC in the
presence of 0.01 mM Ca2 (Fig. 7), but there was
no counteraction of TUDC or GUDC to the com-
bined damage by Ca2 and CDC under these con-
ditions. This may be due to the more polar binding
characteristics of TUDC or GUDC described for
plasma membranes [3], which is probably also valid
for mitochondrial membranes. Naturally, calcium in-
terferes with polar binding sites. Mitochondria, vice
versa, appear to be much more sensitive to TCDC
compared to CDC (Fig. 1).
In general, the in vitro studies presented here sup-
port a transient protective role of UDC, which is
superior to TUDC or GUDC. UDC intercalation
into mitochondrial membranes cannot occur in a
comparable manner and to a comparable, stable ex-
tent as into plasma membranes of the hepatocytes.
Our ¢ndings indicate a direct protection of liver
mitochondrial membranes by UDC which, however,
probably cannot solely account for the sustained de-
crease in serum GLDH. In addition, UDC probably
reduces mitochondrial disruption by changing the
intracellular milieu from the highly toxic calcium/
CDC environment to the less toxic calcium/UDC
environment. This hypothesis is supported by the
observation that the UDC-stimulated calcium entry
across the hepatocellular plasma membrane or liber-
ation from cellular calcium stores is associated with
increased vesicular exocytosis of toxic bile salts
[55,58].
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